{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:02:15Z","timestamp":1794585735119,"version":"4.9.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>T-cell\u2013based immunotherapies have revolutionized treatment paradigms in B-cell malignancies, yet their translation to acute myeloid leukemia (AML) has been hindered by a scarcity of tumor-restricted antigens and the risk of on-target off-leukemia toxicity. FLT3 has emerged as a promising therapeutic target with limited expression in healthy hematopoietic tissues. Here, we performed a head-to-head preclinical comparison of an FMS-like tyrosine kinase 3 (FLT3)-directed bispecific T-cell engager (BiTE) molecule and second-generation FLT3-specific chimeric antigen receptor (CAR) T cells. Both approaches induced potent cytotoxicity against AML cell lines and primary patient-derived cells but spared healthy hematopoietic stem and progenitor cells in vitro. Despite similar short-term efficacy, prolonged antigen exposure demonstrated progressive functional decline and metabolic exhaustion; however, CAR T cells maintained cytotoxic capacity and proliferative potential over time. In AML xenograft models, CAR T cells achieved superior tumor control, prolonged survival, and greater T-cell infiltration than BiTE molecule\u2013treated counterparts. Transcriptomic profiling of T cells recovered from the bone marrow further revealed a distinct exhaustion-associated gene signature in samples from mice that had been treated with the FLT3 BiTE molecule. Importantly, provision of CD86-mediated costimulation enhanced antitumor activity of BiTE-redirected T cells in vitro and in vivo. These findings establish FLT3 as a viable and selective immunotherapeutic target in AML and underscore the functional and transcriptional differences between BiTE molecule\u2013redirected T cells and CAR T cells. Moreover, they reveal a critical role for costimulatory signaling in sustaining the efficacy of T-cell\u2013based therapies in vivo, offering a rationale for improving T cell\u2013redirection strategies in myeloid malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018168","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:00:27Z","timestamp":1764604827000},"page":"1179-1193","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-2896","authenticated-orcid":false,"given":"Lisa","family":"Rohrbacher","sequence":"first","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-9952","authenticated-orcid":false,"given":"Daniel","family":"Nixdorf","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Stadler","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Brauchle","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-0380","authenticated-orcid":false,"given":"Florian","family":"M\u00e4rkl","sequence":"additional","affiliation":[{"name":"3Division of Clinical Pharmacology, University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2898-4182","authenticated-orcid":false,"given":"Adrian","family":"Gottschlich","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"3Division of Clinical Pharmacology, University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany"},{"name":"4German Cancer Consortium, Partner Site Munich and German Cancer Research Center, Heidelberg, Germany"},{"name":"5Bavarian Cancer Research Center, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3167-2124","authenticated-orcid":false,"given":"Gordon V.","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"3Division of Clinical Pharmacology, University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3918-7795","authenticated-orcid":false,"given":"Nora","family":"Philipp","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-6499","authenticated-orcid":false,"given":"Gerulf","family":"H\u00e4nel","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0286-4737","authenticated-orcid":false,"given":"Martin E.","family":"Kirmaier","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"4German Cancer Consortium, Partner Site Munich and German Cancer Research Center, Heidelberg, Germany"},{"name":"6Cancer and Immunometabolism Research Group, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Marcinek","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-4807","authenticated-orcid":false,"given":"Maryam","family":"Kazerani","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Richter","sequence":"additional","affiliation":[{"name":"7Anthropology and Human Genomics, Faculty of Biology, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6006-4758","authenticated-orcid":false,"given":"Giulia","family":"Magno","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"8Amgen Research, Amgen Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-8258","authenticated-orcid":false,"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"4German Cancer Consortium, Partner Site Munich and German Cancer Research Center, Heidelberg, Germany"},{"name":"5Bavarian Cancer Research Center, Munich, Germany"},{"name":"6Cancer and Immunometabolism Research Group, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0547-0453","authenticated-orcid":false,"given":"Tobias","family":"Straub","sequence":"additional","affiliation":[{"name":"9Core Facility Bioinformatics, Biomedical Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-4673","authenticated-orcid":false,"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[{"name":"3Division of Clinical Pharmacology, University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany"},{"name":"4German Cancer Consortium, Partner Site Munich and German Cancer Research Center, Heidelberg, Germany"},{"name":"10Einheit f\u00fcr Klinische Pharmakologie, Helmholtz Munich, Research Center for Environmental Health, Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Arvedson","sequence":"additional","affiliation":[{"name":"8Amgen Research, Amgen Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-7280","authenticated-orcid":false,"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"1Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"2Laboratory for Translational Cancer Immunology, Gene Center, Ludwig Maximilian University Munich, Munich, Germany"},{"name":"4German Cancer Consortium, Partner Site Munich and German Cancer Research Center, Heidelberg, Germany"},{"name":"5Bavarian Cancer Research Center, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"4","key":"2026022411380173800_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","article-title":"Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis","volume":"32","author":"Stelljes","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026022411380173800_bib2","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026022411380173800_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1078-0432.CCR-18-3328","article-title":"First CAR to pass the road test: tisagenlecleucel's drive to FDA approval","volume":"25","author":"Geyer","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026022411380173800_bib4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026022411380173800_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"2026022411380173800_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"2026022411380173800_bib7","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-19-1093","article-title":"Characterization of a novel FLT3 BiTE molecule for the treatment of acute myeloid leukemia","volume":"19","author":"Brauchle","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2026022411380173800_bib8","first-page":"238","article-title":"Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells","volume":"10","author":"Rosnet","year":"1996","journal-title":"Leukemia"},{"issue":"24","key":"2026022411380173800_bib9","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2026022411380173800_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2003-06-1969","article-title":"FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2026022411380173800_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci"},{"issue":"10","key":"2026022411380173800_bib12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026022411380173800_bib13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41375-023-02127-0","article-title":"Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment","volume":"38","author":"H\u00e4nel","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"2026022411380173800_bib14","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00262-023-03439-x","article-title":"CD33 BiTE(\u00ae) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells","volume":"72","author":"Marcinek","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"2026022411380173800_bib15","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41375-024-02387-4","article-title":"Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse","volume":"38","author":"Kazerani","year":"2024","journal-title":"Leukemia"},{"issue":"18","key":"2026022411380173800_bib16","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1038\/s41388-020-1239-y","article-title":"Alterations of T-cell-mediated immunity in acute myeloid leukemia","volume":"39","author":"Li","year":"2020","journal-title":"Oncogene"},{"issue":"3","key":"2026022411380173800_bib17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026022411380173800_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13059-022-02660-8","article-title":"Prime-seq, efficient and powerful bulk RNA sequencing","volume":"23","author":"Janjic","year":"2022","journal-title":"Genome Biol"},{"issue":"8","key":"2026022411380173800_bib19","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/cancers15082233","article-title":"Set protein is involved in FLT3 membrane trafficking","volume":"15","author":"Marcotegui","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2026022411380173800_bib20","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37","author":"Nixdorf","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"2026022411380173800_bib21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"issue":"26","key":"2026022411380173800_bib22","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2026022411380173800_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"2026022411380173800_bib24","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","article-title":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026022411380173800_bib25","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.4049\/jimmunol.180.11.7358","article-title":"Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte\/macrophage progenitor stages to maintain cell survival","volume":"180","author":"Kikushige","year":"2008","journal-title":"J Immunol"},{"issue":"26","key":"2026022411380173800_bib26","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026022411380173800_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1532\/IJH97.05079","article-title":"FLT3 tyrosine kinase inhibitors","volume":"82","author":"Levis","year":"2005","journal-title":"Int J Hematol"},{"issue":"2","key":"2026022411380173800_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/leu.2017.257","article-title":"Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia","volume":"32","author":"Reiter","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2026022411380173800_bib29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","article-title":"Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias","volume":"87","author":"Carow","year":"1996","journal-title":"Blood"},{"issue":"4","key":"2026022411380173800_bib30","first-page":"588","article-title":"Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells","volume":"10","author":"Drexler","year":"1996","journal-title":"Leukemia"},{"issue":"4","key":"2026022411380173800_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev"},{"issue":"9","key":"2026022411380173800_bib32","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","article-title":"Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)","volume":"16","author":"Larson","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"2026022411380173800_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-023-01490-w","article-title":"Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease","volume":"16","author":"Heitmann","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2026022411380173800_bib34","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2026022411380173800_bib35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"8","key":"2026022411380173800_bib36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2026022411380173800_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"issue":"2","key":"2026022411380173800_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol"},{"issue":"2","key":"2026022411380173800_bib39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"11","key":"2026022411380173800_bib40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2026022411380173800_bib41","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunology"},{"key":"2026022411380173800_bib42","doi-asserted-by":"crossref","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"issue":"21","key":"2026022411380173800_bib43","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1179\/2503772\/blooda_adv-2025-018168-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1179\/2503772\/blooda_adv-2025-018168-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:38:13Z","timestamp":1771951093000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1179\/556792\/FLT3-directed-BiTE-molecules-vs-CAR-T-cells-in-AML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018168","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,13]]}}}